Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $848,055.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at $7,874,697.12. This represents a 9.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70.
• On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04.

Alnylam Pharmaceuticals Trading Up 0.0%

ALNY stock opened at $359.27 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 1,496.96 and a beta of 0.32. The business has a fifty day simple moving average of $418.74 and a 200-day simple moving average of $421.35. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $243,000. Geneos Wealth Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 175 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Alnylam Pharmaceuticals by 36.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 196 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 52 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 14.3% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,808 shares of the biopharmaceutical company’s stock worth $4,829,000 after acquiring an additional 1,851 shares in the last quarter. Finally, Swedbank AB boosted its holdings in Alnylam Pharmaceuticals by 7.2% in the second quarter. Swedbank AB now owns 64,315 shares of the biopharmaceutical company’s stock valued at $20,972,000 after purchasing an additional 4,322 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several research analyst reports. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. HC Wainwright set a $570.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Barclays upped their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.